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Sir,  25 
 26 
Ceftolozane/Tazobactam (C/T) is a cephalosporin and β-lactamase inhibitor with 27 
potent activity against Pseudomonas aeruginosa [1]. There is limited experience with 28 
C/T as a continuous infusion, and as such, to ensure attainment of pharmacodynamic 29 
targets, therapeutic drug monitoring (TDM) should be undertaken. It is unknown 30 
whether temperature or other deviations that occur when the infusion is run in the 31 
community affect overall drug stability and exposure. Here we report a case of a 32 
patient who received C/T where drug concentrations were measured in the hospital 33 
and then later in the community. 34 
 35 
A 58 year-old male with a renal transplant was admitted to a tertiary referral hospital 36 
following subacute fevers. No prior infections were noted. On admission, computed 37 
tomography of his chest revealed a four-centimetre cavitating lung lesion within the 38 
right upper lobe of the lung. A pan-susceptible Pseudomonas aeruginosa was isolated 39 
via bronchoscopy and initial therapy of meropenem 1g IV three times daily was 40 
commenced. His clinical condition worsened and he required inotropic support in the 41 
intensive care unit (ICU). He developed acute kidney injury with a serum creatinine 42 
rise to 231 μmol/L (baseline serum creatinine 96 μmol/L), however, did not require 43 
renal replacement therapy. He was discharged to a medical ward and went on to 44 
complete a total of fourteen days of meropenem. Five days after cessation of 45 
antibiotic therapy the patient became febrile. Repeat imaging of his chest revealed 46 
progression of the cavitating lung abscess. An induced sputum sample taken revealed 47 
a P. aeruginosa isolate resistant to meropenem, ciprofloxacin and ceftazidime. The 48 
C/T MIC was determined by E-Test as 2 mg/L (susceptible) and the patient was 49 
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commenced on a 3/1.5g per 24-hour continuous C/T infusion. The infusion 50 
composition was C/T 3g/1.5g in (final volume) 300mL 0.9% sodium chloride and 51 
administered via a CADD pump. Following clinical and biochemical improvement 52 
(C-reactive protein <2mg/L), he was planned for discharge to his home in via an 53 
Outpatient Parenteral Antibiotic Therapy (OPAT) service. Repeat imaging of his 54 
chest after 42 days of C/T therapy revealed a significant reduction in size of the 55 
cavitating lung lesion.  56 
 57 
Three blood samples were taken at pharmacokinetic steady state (after 24-hours of 58 
ceftolozane continuous infusion therapy), initially while the patient was an inpatient, 59 
then two weeks later whilst on the OPAT program. This occurred during April 2017 60 
(local reported temperatures ranged from 13.0-29.0 degrees Celsius [2]) with samples 61 
separated by at least 4-hours. Drug concentrations of ceftolozane and tazobactam in 62 
plasma were measured by a validated UHPLC-MS/MS method on a Shimadzu 63 
Nexera2 UHPLC system coupled to a Shimadzu 8030+ triple quadrupole mass 64 
spectrometer. The mean + SD drug concentrations in the hospital and community 65 
were 37.3 + 1.4 versus 34.8 + 0.2 for ceftolozane and 6.57 + 1.78 versus 7.66 + 0.79 66 
mg/L for tazobactam respectively. The individual patient concentrations are shown in 67 
Figure 1a and 1b. 68 
 69 
This is the first known report of C/T continuous infusion therapy used to treat a multi-70 
drug resistant Pseudomonas aeruginosa pulmonary infection. This report outlines the 71 
successful use of a long course of C/T in an immunosuppressed patient delivered 72 
through an OPAT service. There did not appear to be a significant difference in 73 
unbound drug concentrations measured in the hospital as compared with the 74 
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community setting, as well as between designated time points throughout the day 75 
(minimum 4-hour gap between samples). 76 
 77 
There have been only two reports of the successful use of C/T as a continuous 78 
infusion [3]. C/T is known to be stable for at least 24 hours at room temperature 79 
making it a suitable candidate for continuous infusion [3]. A study evaluating the 80 
stability of C/T in elastomeric pumps determined physical and chemical stability of at 81 
least 7 days with greater than 93% drug recovery at this time [4].  82 
 83 
Recommended dosing of C/T in patients with a creatinine clearance of >50ml/min is 84 
1.5g, over a 1-hour infusion, every 8 hours [4]. The decision to use the standard dose 85 
(3g/1.5g) in this patient was due to his low body weight (approx. 65kg), creatinine 86 
clearance of 55 mL/min and that the patient was not critically unwell at the time of 87 
treatment initiation. The unbound ceftolozane concentrations in plasma were well 88 
above the 4-5 times the MIC value that is associated with maximal bacterial killing. 89 
The mean penetration of ceftolozane into epithelial lining fluid is suggested to be 50% 90 
of plasma concentrations [5]. Using this figure, the concentrations were likely to be 91 
greater than 4-5 times the MIC at the site of infection for the full dosing interval.  92 
 93 
C/T as a continuous infusion administered in the community setting was found to be 94 
effective in the treatment of a carbapenem-resistant P. aeruginosa lung abscess. More 95 
investigations are required to characterise the pharmacokinetics of C/T in different 96 
patient populations as well as its stability in different clinical scenarios to further 97 
optimise its use.  98 
 99 
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FIGURES 125 
 126 
1. Unbound Ceftolozane/Tazobactam plasma concentrations (mg/L) in both 127 
hospital and community settings using a continuous infusion of 3/1.5g over 128 
twenty-four hours (samples taken two weeks apart) 129 
 130 
 131 
1a. Hospital  132 
 133 
 134 
 135 
1b. Community  136 
 137 
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